Company
Sight Sciences
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
11
510(k), De Novo and PMA
Device trials
17
As lead sponsor, any status
Adverse event reports
21
Received Nov 1, 2025 to Nov 19, 2026
Recall records
1
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
SGHT
Nasdaq · Sight Sciences, Inc.
Public float
$154M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$77.4M
Fiscal year ending Dec 31, 2025
Net income
-$38.4M
Fiscal year ending Dec 31, 2025
R&D spending
$14.6M
Fiscal year ending Dec 31, 2025
Cash
$77.4M
As of Sep 30, 2026
Long-term debt
$42.4M
As of Sep 30, 2026
Shares outstanding
55.6M
As of Oct 29, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2021 | $257M | – | – | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Nov 23, 2020 | Equity | $23.2M | $23.2M | 4 | Rule 506(b) | Form D ↗Dec 10, 2020 |
| Mar 17, 2020 | Equity | $30.2M | $30.5M | 0 | Rule 506(b) | Form D/A ↗Apr 14, 20201 amendment |
| Aug 9, 2019 | Equity | $30.7M | $31.5M | 2 | Rule 506(b) | Form D/A ↗Sep 10, 20191 amendment |
| Jul 7, 2017 | Equity | $19.7M | $22.2M | 25 | Rule 506(b) | Form D/A ↗Jun 4, 20181 amendment |
| Oct 16, 2015 | Equity | $6.9M | $7.0M | 17 | Rule 506(b) | Form D ↗Oct 30, 2015 |
| Sep 12, 2011 | Equity | $525K | $5.2M | 6 | Rule 506 | Form D ↗Sep 28, 2011 |
Company details
From the company's latest Form D.
- Legal name
- Sight Sciences, Inc.
- Headquarters
- Menlo Park, California
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1531177 ↗
Executives, directors and promoters
As listed on the latest Form D.
- Paul BadawiExecutive Officer, Director
- Jesse SelnickExecutive Officer
- David BadawiDirector
- Staffan EncrantzDirector
- Mack HicksDirector
- Valeska SchroederDirector
- Erica RogersDirector
- Andrew OfferDirector
- Don ZurbayDirector
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
The investor database is part of the paid tier
It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.
Latest FDA decisions
The 8 newest of 11 since 2015.
- TearCare System510(k)
K262479 · Decided Aug 18, 2026 · 29 days after receipt
Device type: Eyelid Thermal Pulsation System (ORZ) · Ophthalmology
K253760 · Decided Aug 4, 2026 · 252 days after receipt
Device type: Pump, Infusion, Ophthalmic (MRH) · Hospital Medicine & Nursing
- TearCare MGX System510(k)
K252409 · Decided Apr 27, 2026 · 269 days after receipt
Device type: Eyelid Thermal Pulsation System (ORZ) · Ophthalmology
- TearCare MGX System510(k)
K242786 · Decided Apr 15, 2025 · 211 days after receipt
Device type: Eyelid Thermal Pulsation System (ORZ) · Ophthalmology
- TearCare MGX System510(k)
K231084 · Decided Dec 27, 2023 · 254 days after receipt
Device type: Eyelid Thermal Pulsation System (ORZ) · Ophthalmology
- OMNI Surgical System510(k)
K232214 · Decided Aug 25, 2023 · 30 days after receipt
Device type: Pump, Infusion, Ophthalmic (MRH) · Hospital Medicine & Nursing
- TearCare System510(k)
K213045 · Decided Dec 21, 2021 · 90 days after receipt
Device type: Eyelid Thermal Pulsation System (ORZ) · Ophthalmology
- OMNI Surgical System510(k)
K202678 · Decided Mar 1, 2021 · 167 days after receipt
Device type: Pump, Infusion, Ophthalmic (MRH) · Hospital Medicine & Nursing
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)Completed
NCT06948773 · 25 participants · Start May 21, 2025 · Primary completion Sep 7, 2026
Device: Helix Surgical System · For: Primary Open Angle Glaucoma; Cataract
Sites: Panama City, Panama
NCT07365735 · 21 participants · Start Mar 17, 2026 · Primary completion May 19, 2026
Device: localized heat therapy · For: Meibomian Gland Dysfunction (Disorder)
Sites: Brecksville, Ohio
- OMNI 3.1 Surgical System in Subjects With Primary Open-Angle GlaucomaActive, not recruiting
NCT06991270 · 25 participants (planned) · Start Oct 8, 2025 · Primary completion Dec 1, 2026
Device: OMNI 3.0 Surgical System · For: Primary Open Angle Glaucoma
Sites: Panama City, Panama
- Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)Pivotal-lookingCompleted
NCT04795752 · 345 participants · Start Apr 28, 2021 · Primary completion Sep 23, 2024
Device: TearCare System · For: Dry Eye; Meibomian Gland Dysfunction
Sites: Scottsdale, Arizona; La Jolla, California; Laguna Hills, California · 14 sites in all
- Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle GlaucomaTerminated
NCT02928289 · 29 participants · Start Jan 23, 2017 · Primary completion Jan 17, 2019
Device: VISCO360 ab interno canaloplasty surgery; Selective Laser Trabeculoplasty (SLT) · For: Open-Angle Glaucoma
Sites: Fayetteville, Arkansas; Orange, California; Oklahoma City, Oklahoma · 6 sites in all
NCT03804502 · 12 participants · Start Dec 17, 2018 · Primary completion May 21, 2019
Device: TearCare · For: Dry Eye Syndromes
Sites: Arlington Heights, Illinois
Reports received
21
Received Nov 1, 2025 to Nov 19, 2026. Includes 1 of another or unstated type.
Malfunction reports
4
19% of reports
Injury reports
16
76% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 1 | 1 | 0 | 0 |
| Feb 24 | 0 | 3 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 2 | 0 | 0 |
| May 24 | 0 | 1 | 0 | 0 |
| Jun 24 | 1 | 1 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 2 | 1 | 0 | 0 |
| Sep 24 | 1 | 1 | 0 | 0 |
| Oct 24 | 1 | 4 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 3 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 1 | 2 | 0 | 0 |
| May 25 | 0 | 1 | 0 | 0 |
| Jun 25 | 0 | 1 | 0 | 0 |
| Jul 25 | 0 | 3 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 1 | 0 | 0 |
| Oct 25 | 0 | 2 | 0 | 0 |
| Nov 25 | 0 | 1 | 0 | 0 |
| Dec 25 | 1 | 2 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 1 | 0 | 0 |
| Apr 26 | 1 | 0 | 0 | 0 |
| May 26 | 1 | 3 | 0 | 0 |
| Jun 26 | 1 | 1 | 0 | 0 |
| Jul 26 | 0 | 2 | 0 | 0 |
| Aug 26 | 0 | 3 | 0 | 1 |
| Sep 26 | 0 | 2 | 0 | 0 |
| Oct 26 | 0 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- TearCare version 1.0 SmartHubsOpen, Classified
Z-1001-2022 · Started Mar 23, 2022
Reason given: Ophthalmic devices distributed prior to the recently-obtained 510(k) clearance do not fall within the relevant 510(k) exemption and so their performance characteristics were not evaluated by the FDA prior to distribution.
Cause as FDA categorized it: No Marketing Application · Device type: Eyelid Thermal Pulsation System (ORZ)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.